Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Binimetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | SMC2 | O95347 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.84 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.84 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.84 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.84 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.84 |
| ▸ | BRAF | P15056 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Binimetinib SCHEMBL29363187 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL25189605 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29990127 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL25020586 | 0.92 | MAP2K1 (0.85) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| Selumetinib SCHEMBL29555068 | 0.91 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL25480020 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| Selumetinib SCHEMBL29353582 | 0.91 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| Selumetinib SCHEMBL155456 | 0.91 | MAP2K1 (1.00) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL15704258 | 0.91 | MAP2K1 (0.84) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29199685 | 0.91 | MAP2K1 (0.83) | MAP2K1MAP2K2ABCB11NQO2SMC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| WO-2018126192-A1 | MAP2K1 (MEK1) AS A THERAPEUTIC TARGET FOR ARTERIOVENOUS MALFORMATIONS AND ASSOCIATED DISORDERS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-07-05 | — | — | WO | claimed |
| US-20170296659-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-10-19 | — | — | US | claimed |
| EP-3191097-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-07-19 | — | — | EP | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2017044483-A1 | METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-16 | — | — | WO | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2016040892-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |